Asher Biotherapeutics

Asher Biotherapeutics company information, Employees & Contact Information

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

Company Details

Employees
26
Address
South San Francisco, South San Francisco,california,united States
Phone
650.416.6789
Email
fo****@****Bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco , California
Looking for a particular Asher Biotherapeutics employee's phone or email?

Asher Biotherapeutics Questions

News

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer - Business Wire

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer Business Wire

Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) - Business Wire

Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) Business Wire

Asher drops 60% of staff as immunotherapy biotech zeroes in on lead candidate - Fierce Biotech

Asher drops 60% of staff as immunotherapy biotech zeroes in on lead candidate Fierce Biotech

Asher Bio Appoints Bob Deresiewicz, M.D., To Its Board - citybiz

Asher Bio Appoints Bob Deresiewicz, M.D., To Its Board citybiz

Asher Bio adds $55M and takes a page from nature for cancer immunotherapy - MedCity News

Asher Bio adds $55M and takes a page from nature for cancer immunotherapy MedCity News

Asher Bio snags $108M series B for immunotherapy programs, push into the clinic - Fierce Biotech

Asher Bio snags $108M series B for immunotherapy programs, push into the clinic Fierce Biotech

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials - Business Wire

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials Business Wire

New twist on old cancer target brings $55M to 'happy, blessed' startup by Pfizer vets - The Business Journals

New twist on old cancer target brings $55M to 'happy, blessed' startup by Pfizer vets The Business Journals

Asher Bio sets out with $55M to deliver the pros of cytokines, other immunotherapies without the cons - Fierce Biotech

Asher Bio sets out with $55M to deliver the pros of cytokines, other immunotherapies without the cons Fierce Biotech

YC Demo Day 2: All 25 Bay Area pitches, from a hot virtual office startup to a cool stroke treatment - The Business Journals

YC Demo Day 2: All 25 Bay Area pitches, from a hot virtual office startup to a cool stroke treatment The Business Journals

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer - Business Wire

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer Business Wire

Top Asher Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant